For most of the twentieth century, the pharmaceutical industry’s relationship with rare diseases could be summarised in a single phrase: studied indifference. The economics were simply prohibitive. Small patient populations meant limited revenue potential; limited revenue meant that even promising science rarely attracted the capital needed to progress from laboratory to clinic. The FDA estimated that in the decades before 1983, patients with rare conditions experienced what it termed “pharmacologic neglect” – a situation in which academic researchers occasionally discovered promising therapies but could rarely find a commercial partner willing to bring them to market. Fewer than ten orphan drugs had been approved in the entire decade before legislative intervention changed the calculus.
It is important to understand, from the outset, that this indifference was not callousness. It was commercial logic. Pharmaceutical companies operate within a framework of fiduciary responsibility, in which investment decisions must be justified by a credible path to return. Rare diseases, in the absence of supportive legislation and the network infrastructure that has since developed, simply could not meet that test. Understanding how and why that changed – and the limits of how far it has changed – requires holding that commercial reality in mind throughout.
The Legislative Turning Point
The Orphan Drug Act, signed into law by President Reagan on 4 January 1983, did not immediately transform pharmaceutical attitudes. What it did was create, for the first time, a commercial logic for engagement. Seven-year market exclusivity, tax credits covering half of clinical development costs, and expedited FDA review together shifted the risk-return profile of orphan drug development sufficiently to attract serious attention. Japan followed with its own orphan drug legislation in 1993 and the European Union in 2000, creating an increasingly coherent international framework.
The numbers tell part of the story. Prior to the Act, only approximately two drugs per year had been approved by the FDA for rare diseases. In the four decades since, over 6,300 orphan drug designations have been granted, covering drug development for more than 1,000 rare diseases. Yet it would be a mistake to read this as evidence that commercial caution had been set aside. What the legislation achieved was not to make pharmaceutical companies indifferent to risk, but to restructure it – by reducing the investment required, extending the period of market protection, and improving the predictability of the regulatory pathway. Companies were not abandoning their commercial frameworks; they were finding, for the first time, that rare diseases could fit within them.
The Pioneers: Building the Model
The companies that first understood this were not the large diversified pharmaceutical firms, whose risk frameworks and portfolio requirements made rare diseases difficult to justify at scale. They were specialist biotechs willing to commit entirely to rare diseases as both a scientific and commercial focus – organisations whose entire strategic identity was built around the rare disease space, and for whom the networks surrounding rare diseases were not an add-on but the core of their operating model.
Genzyme, founded in Boston in 1981, became the defining proof of concept. Its development of imiglucerase, an enzyme replacement therapy for Gaucher disease, demonstrated that rare diseases were not merely tractable scientifically but commercially viable. This came about in part because the company invested deeply in the patient and clinical communities around Gaucher disease, building the registries, natural history data, and specialist relationships that no regulatory submission could have been constructed without. Henri Termeer, who led Genzyme for nearly three decades, understood this dependency instinctively. “Patients are absolutely the essential ingredient,” he said, “and they are the biggest difference between what we have in the rare disease community versus what you have in the other, much broader-based disease areas.” Crucially, this investment was not altruistic; it was strategically rational. Without those networks, the data needed to support development simply did not exist.
The same model was extended to Fabry disease, Pompe disease, and MPS I. When Sanofi acquired Genzyme in 2011 for $20.1 billion, it was acquiring not just a product portfolio but three decades of embedded network relationships – and the commercial returns those relationships had made possible. BioMarin Pharmaceutical, founded in 1997 and focused exclusively on rare genetic disorders, carried the same philosophy forward. Ultragenyx, founded in 2010 by Emil Kakkis, built its entire operating model around disease-specific communities, patient registries, and close collaboration with the handful of clinicians worldwide who held the accumulated expertise in each condition it targeted. In each case, deep network engagement was inseparable from commercial strategy.
Large Pharma’s Gradual Conversion
For the larger pharmaceutical companies, conversion to rare diseases was slower, more deliberate, and almost always driven by a clear strategic rationale rather than opportunism. The acquisitions that brought rare disease capability inside major companies were not acts of altruism; they were calculated bets, made when the commercial case had become sufficiently clear and when the target company offered not just products but the network infrastructure that rare disease development requires.
Pfizer established a dedicated rare disease division in 2010, following an assessment that its existing platform technologies in certain therapeutic areas could be extended into rare disease indications at acceptable incremental risk. AstraZeneca made its most emphatic statement in 2021, acquiring Alexion Pharmaceuticals – a pioneer in complement biology founded in 1992 – for $39 billion, its largest acquisition to date. The decision was explicitly strategic: AstraZeneca’s leadership judged that Alexion’s complement portfolio, combined with its rare disease network relationships and commercial infrastructure, offered a risk-adjusted return that justified the premium. The deal created the division ‘Alexion, AstraZeneca Rare Disease’, and signalled that even companies with no prior heritage in the space were willing to make transformative commitments provided the strategic alignment was demonstrably there.
These moves reflected a broader industry reassessment, but one that remained disciplined. Companies did not enter rare diseases indiscriminately. The conditions that attracted investment were those where scientific understanding was sufficiently advanced, where network infrastructure existed to support development, and where the regulatory and commercial pathways were navigable. It is worth reiterating that the majority of the world’s approximately 7,000 rare diseases are those without patient registries, established clinical networks, or well-characterised natural histories – and thus they largely remain without pharmaceutical investment.
Why Networks Became Indispensable
The shift in commercial attitude brought with it a more fundamental realisation: that rare disease development, unlike mainstream pharmaceutical R&D, could not be conducted in isolation from the communities it was designed to serve. Patient populations were small and geographically dispersed. Clinical expertise was concentrated in a handful of specialist centres. Data was sparse, inconsistent, and often existed only because patient organisations had invested years in collecting it.
In this environment, rare disease networks – connecting patients, clinicians, researchers, regulators, and industry – were not optional infrastructure. They were the mechanism through which development was possible at all, and therefore the mechanism through which commercial risk could be managed to an acceptable level. They enabled data aggregation across populations too small for any single site to study meaningfully. They standardised clinical understanding across health systems that might otherwise develop entirely divergent practices. They provided the patient-derived insight into meaningful endpoints that regulatory agencies were increasingly demanding, and without which trial designs could be fatally flawed.
For pharmaceutical companies, engagement with these networks was therefore not a philanthropic gesture but a risk management strategy. Patient organisations in particular came to be seen not as lobbying bodies to be managed at arm’s length but as indispensable partners whose involvement could make the difference between a trial that generated approvable evidence and one that did not.
The Landscape Today – and Its Tensions
The transformation has been substantial. Rare diseases now account for an estimated 35% of all drugs and biologics in the global R&D pipeline, a figure that would have been unimaginable at the time the Orphan Drug Act was passed. The networks that pharmaceutical companies once observed cautiously are now, for the most committed players, deeply embedded in how they operate.
Yet the relationship is not without tension. The same market exclusivity and premium pricing that made rare disease development commercially attractive are increasingly scrutinised by payers and health technology assessment bodies facing the cumulative cost of approving hundreds of high-price therapies for small populations. Access and affordability have become urgent questions that network engagement alone cannot resolve. And the concentration of rare disease investment in oncology and a relatively small number of well-characterised conditions means that the majority of patients with rare diseases remain without any approved treatment.
Within the industry, there is growing recognition that rare disease networks also serve as platforms for the constructive, multi-stakeholder dialogue that these tensions demand. The questions of pricing, access, evidence standards, and value will not be resolved by any single company or regulatory body. They require exactly the kind of sustained, cross-sector collaboration that rare disease networks were built to enable.
A Relationship Still Maturing
The history of pharmaceutical involvement in rare disease networks is ultimately a story of commercial risk being gradually, and only partially, tamed. Industry needed the data, expertise, and patient insight that only networks could provide. Networks needed the capital, development capability, and regulatory expertise that only industry could bring. The specialist pioneers of the 1980s and 1990s understood this mutual dependency instinctively, and built business models around it. The larger companies that followed have had to learn it, often through the billion-dollar acquisitions that brought network-embedded businesses inside their own walls.
Critically, that engagement has always been conditional. Pharmaceutical companies invest in rare disease networks when doing so demonstrably reduces development risk, improves the probability of regulatory success, and aligns with a broader strategic platform. When those conditions are not met – when a disease is too poorly understood, the patient community too fragmented, or the commercial pathway too uncertain – investment does not follow, regardless of medical need. This is not a failing unique to the pharmaceutical industry; it is a structural reality of how private capital operates.
That process of conditional, strategically-driven engagement is ongoing. The networks that pharmaceutical companies engage with today are more sophisticated, more international, and more demanding than those of thirty years ago. Whether industry engagement deepens further, or plateaus under the pressure of pricing scrutiny, tightening reimbursement frameworks, and therapeutic area prioritisation, will be one of the defining questions of rare disease development in the decade ahead.
Next in the series: How regulators have adapted their frameworks to meet the unique evidentiary challenges of rare disease development – and what that means for patients waiting for treatments.
